Metropolis Healthcare Limited has informed the Exchange that Record date for the purpose of Dividend is 11-Nov-2025.
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.4 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Metropolis Healthcare's board approved Q2 FY26 results with consolidated revenue of Rs 429 crore, up about 23% year-on-year, boosted by recent acquisitions and organic growth. Standalone revenue rose nearly 11% to Rs 356 crore, while standalone profit after tax grew around 10% to Rs 47 crore; on a consolidated basis, PAT rose about 13% to Rs 53 crore. The board declared an interim dividend of Rs 4 per share (on a Rs 2 face value), with November 11, 2025 fixed as the record date and payout within 30 days. The company completed three business acquisitions during the period — Dapic, Scientific Metropolis, and an Ambika Pathology lab in Kolhapur — with combined consideration of roughly Rs 87 crore. Statutory auditors BSR & Co. issued an unmodified limited review report on both the standalone and consolidated results, with no qualifications or concerns flagged.
Strong double-digit revenue growth and a confirmed interim dividend are positive for shareholders, though standalone and consolidated EBITDA margins saw a modest compression of roughly 100-120 basis points year-on-year, which is worth monitoring as integration costs from new acquisitions are absorbed.